Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies. Ghobadi A, Aldoss I, Maude SL, Bhojwani D, et al. Blood 2025;146:1163-1173.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ghobadi A, Aldoss I, Maude SL, Bhojwani D, et al. Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies. Blood 2025;146:1163-1173.
PMID: 40445850